🔗 Share this article

As America continues making sweeping adjustments to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning coronavirus vaccines during the pandemic and has focused upon possible deaths following COVID-19 vaccination in her short tenure at the FDA.

Scheduled Shifts to Childhood Vaccine Schedule

Public health authorities had intended to reveal major revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A Shift at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for ending certain childhood immunization guidelines in the US to become more in line with Denmark, a society with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Dr. Høeg has no obvious background in drug development, approval processes or administrative roles, which has been customary for former directors of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a major agency. She lacks background in industry regulation.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the science of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic program clears thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a substantial management component to the position, which manages over 5,000 personnel. “It is a enormous leadership role, if you execute it properly,” Woodcock concluded.

Official Statement and Contentious Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a representative responded that the “questions are based on inaccurate assumptions”.

“Her experience matches the responsibilities of her job,” the spokesperson explained, noting the months Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a controversial one-day therapy clearance system that reportedly worried her predecessors. “How are these drugs being selected for this voucher program? Who is making the choices?” Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of most medications, with the exception of vaccines.”

Public Past Work on Vaccines

Regarding immunizations, Høeg has a more documented, if concerning, history, some experts have noted. She authored a analysis using unconfirmed volunteer-provided data to determine the frequency of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming federal leadership encompassed changing rules for recently developed shots and halting “optional” vaccines, she said after the election on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding adolescent males from receiving Covid vaccines.

“She’s an thorough ideologue who begins with her preconceived notions and works backwards to retrofit the science in a very deceptive, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|